Prostate cancer staging: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
No edit summary
 
(59 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{Search infobox}}
__NOTOC__
{{SCC}}
{{CMG}} {{AE}} {{SCC}} {{sali}}
 
{{Prostate cancer}}
{{Editor Join}}
 
==Overview==
==Overview==
 
Prostate cancer may be classified into several subtypes based on [[TNM system]] and [[UICC]].
'''Prostate cancer staging''' is the process by which physicians evaluate the spread of [[prostate cancer]]. This is important because in a good [[cancer staging]] system, the stage of disease helps determine [[prognosis]] and assists in selecting therapies. A combination of [[physical examination]], [[blood tests]], and [[medical imaging]] is used to determine the clinical stage; if tissue is obtained via [[biopsy]] or [[surgery]], examination of the tissue under a microscope can provide pathologic staging.
 
There are two schemes commonly used to stage prostate cancer. The most common is the [[TNM]] system, which evaluates the size of the [[tumor]], the extent of involved [[lymph node]]s, and any [[metastasis]] (distant spread). As with many other cancers, these are often grouped into four stages (I–IV). Another scheme, used less commonly, is the Whitmore-Jewett stage.
 
Briefly, Stage I disease is cancer that is found incidentally in a small part of the sample when prostate tissue was removed for other reasons, such as [[benign prostatic hypertrophy]], and the cells closely resemble normal cells and the gland feels normal to the examining finger. In Stage II  more of the prostate is involved and a lump can be felt within the gland. In Stage III, the tumor has spread through the [[prostatic capsule]] and the lump can be felt on the surface of the gland. In Stage IV disease, the tumor has invaded nearby structures, or has spread to lymph nodes or other organs. Grading is based on cellular content and tissue architecture from biopsies (Gleason) which provides an estimate of the destructive potential and ultimate prognosis of the disease.


==TNM staging==
==TNM staging==
From the [[American Joint  Committee on Cancer|AJCC]] 6th edition (2002) and [[International Union Against Cancer|UICC]] 6th edition.
===Evaluation of the (primary) tumor ('T')===


*'''TX''': cannot evaluate the primary tumor
'''Evaluation of the (primary) tumor ('T')'''<ref name=”cancergov”>National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq</ref>
*'''T0''': no evidence of tumor
*'''T1''': tumor present, but not detectable clinically or with imaging
**'''T1a''': tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons)
**'''T1b''': tumor was incidentally found in greater than 5% of prostate tissue resected
**'''T1c''': tumor was found in a [[needle biopsy]] performed due to an elevated serum [[prostate-specific antigen|PSA]]
*'''T2''': the tumor can be felt (palpated) on examination, but has not spread outside the prostate
**'''T2a''': the tumor is in half or less than half of one of the prostate gland's two [[lobe]]s
**'''T2b''': the tumor is in more than half of one lobe, but not both
**'''T2c''': the tumor is in both lobes
*'''T3''': the tumor has spread through the prostatic [[capsule]] (if it is only part-way through, it is still '''T2''')
**'''T3a''': the tumor has spread through the capsule on one or both sides
**'''T3b''': the tumor has invaded one or both [[seminal vesicle]]s
*'''T4''': the tumor has invaded other nearby structures


It should be stressed that the designation "T2c" implies a tumor which is ''palpable'' in both lobes of the prostate. Tumors which are found to be bilateral on biopsy only but which are not palpable bilaterally should not be staged as T2c.
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|T}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" |TX
| style="padding: 5px 5px; background: #F5F5F5;" |Cannot evaluate the primary [[tumor]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T0
| style="padding: 5px 5px; background: #F5F5F5;" |No evidence of tumor
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T1
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor present, but not detectable clinically or with imaging
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T1a
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor was incidentally found in less than 5% of prostate [[tissue]] resected (for other reasons)
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T1b
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor was incidentally found in greater than 5% of prostate tissue resected
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T1c
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor was found in a [[needle biopsy]] performed due to an elevated serum [[prostate-specific antigen|PSA]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor can be felt (palpated) on examination, but has not spread outside the prostate
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2a
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor is in half or less than half of one of the prostate gland's two [[lobe]]s
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2b
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor is in more than half of one lobe, but not both
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2c
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor is in both lobes
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T3
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has spread through the prostatic [[capsule]] (if it is only part-way through, it is still T2)
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T3a
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has spread through the [[capsule]] on one or both sides
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T3b
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has invaded one or both [[seminal vesicle]]s
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T4
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has invaded other nearby structures
|}


===Evaluation of the regional lymph nodes ('N')===
'''Evaluation of the regional lymph nodes ('N')'''
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
*'''NX''': cannot evaluate the regional lymph nodes
|valign=top|
*'''N0''': there has been no spread to the regional lymph nodes
|+
*'''N1''': there has been spread to the regional lymph nodes
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|N}}
 
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
===Evaluation of distant metastasis ('M')===
*'''MX''': cannot evaluate distant metastasis
*'''M0''': there is no distant metastasis
*'''M1''': there is distant metastasis
**'''M1a''': the cancer has spread to lymph nodes beyond the regional ones
**'''M1b''': the cancer has spread to [[bone]]
**'''M1c''': the cancer has spread to other sites (regardless of bone involvement)
 
===Evaluation of the histologic grade ('G')===
Usually, the [[Grading (tumors)|grade]] of the cancer (how different the tissue is from normal tissue) is evaluated separately from the stage; however, for prostate cancer, grade information is used in conjunction with TNM status to group cases into four overall stages.
 
*'''GX''': cannot assess grade
*'''G1''': the tumor closely resembles normal tissue ([[Gleason score|Gleason]] 2&ndash;4)
*'''G2''': the tumor somewhat resembles normal tissue (Gleason 5&ndash;6)
*'''G3&ndash;4''': the tumor resembles normal tissue barely or not at all (Gleason 7&ndash;10)
 
 
Of note, this system of describing tumors as "well-", "moderately-", and "poorly-" differentiated based on Gleason score of 2-4, 5-6, and 7-10, respectively, persists in SEER and other databases but is generally outdated. In recent years pathologists rarely assign a tumor a grade less than 3, particularly in biopsy tissue. A more contemporary consideration of Gleason grade is:
 
* Gleason 3+3: tumor is low grade (favorable prognosis)
* Gleason 3+4 / 3+5: tumor is mostly low grade with some high grade
* Gleason 4+3 / 5+3: tumor is mostly high grade with some low grade
* Gleason 4+4 / 4+5 / 5+4 / 5+5: tumor is all high grade
 
===Overall staging===
 
The tumor, lymph node, metastasis, and grade status can be combined into four stages of worsening severity.
 
{| class="wikitable"
! Stage !! Tumor !! Nodes !! Metastasis !! Grade
|- style="border-top:2px black solid"
! Stage I
| T1a || N0 || M0 || G1
|- style="border-top:2px black solid"
! rowspan="5" | Stage II
| T1a || N0 || M0 || G2&ndash;4
|-
|-
| T1b || N0 || M0 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |NX
| style="padding: 5px 5px; background: #F5F5F5;" |Cannot evaluate the regional [[lymph nodes]]
|-
|-
| T1c || N0 || M0 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |There has been no spread to the regional lymph nodes
|-
|-
| T1 || N0 || M0 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |N1
| style="padding: 5px 5px; background: #F5F5F5;" |There has been spread to the regional lymph nodes
|}
 
'''Evaluation of distant metastasis ('M')'''
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|M}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
|-
| T2 || N0 || M0 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |M0
|- style="border-top:2px black solid"
| style="padding: 5px 5px; background: #F5F5F5;" |There is no distant metastasis
! Stage III
| T3 || N0 || M0 || Any G
|- style="border-top:2px black solid"
! rowspan="3" | Stage IV
| T4 || N0 || M0 || Any G
|-
|-
| Any T || N1 || M0 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |M1
| style="padding: 5px 5px; background: #F5F5F5;" |There is distant metastasis
|}
 
==UICC staging==
The [[UICC]] further groups the [[TNM]] data into the stages listed in the table below:<ref>{{Cite web | title =Stages of prostate cancer| url =http://www.cancer.ca/en/cancer-information/cancer-type/prostate/staging/?region=ab }}</ref>
* '''Stage I'''
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|T}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|N}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|M}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
|-
| Any T || Any N || M1 || Any G
| style="padding: 5px 5px; background: #DCDCDC;" |T1, T2a
| style="padding: 5px 5px; background: #DCDCDC;" |N0
| style="padding: 5px 5px; background: #DCDCDC;" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] involves half a [[lobe]] or less
|}
|}


==Whitmore-Jewett staging==
* '''Stage II'''
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|T}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|N}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|M}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2b, T2c
| style="padding: 5px 5px; background: #DCDCDC;" |N0
| style="padding: 5px 5px; background: #DCDCDC;" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] involves more than half a lobe but is limited to the prostate
|}


The Whitmore-Jewett system is similar to the TNM system, with approximately equivalent stages. [[Roman numeral]]s are sometimes used instead of Latin letters for the overall stages (for example, Stage I for Stage A, Stage II for Stage B, and so on).
* '''Stage III'''
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|T}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|N}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|M}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T3
| style="padding: 5px 5px; background: #DCDCDC;" |N0
| style="padding: 5px 5px; background: #DCDCDC;" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] has spread beyond the prostatic [[capsule]] or into the [[bladder]] neck or [[seminal vesicles]]
|}


*'''A''': tumor is present, but not detectable clinically; found incidentally
* '''Stage IV'''
**'''A1''': tissue resembles normal cells; found in a few chips from one lobe
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align=center
**'''A2''': more extensive involvement
|valign=top|
*'''B''': the tumor can be felt on physical examination but has not spread outside the [[prostatic capsule]]
|+
**'''BIN''': the tumor can be felt, it does not occupy a whole lobe, and is surrounded by normal tissue
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|T}}
**'''B1''': the tumor can be felt and it does not occupy a whole lobe
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|N}}
**'''B2''': the tumor can be felt and it occupies a whole lobe or both lobes
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|M}}
*'''C''': the tumor has extended through the capsule
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Definition}}
**'''C1''': the tumor has extended through the capsule but does not involve the seminal vesicles
|-
**'''C2''': the tumor involves the seminal vesicles
| style="padding: 5px 5px; background: #DCDCDC;" |T4
*'''D''': the tumor has spread to other organs
| style="padding: 5px 5px; background: #DCDCDC;" |N0
 
| style="padding: 5px 5px; background: #DCDCDC;" |M0
==Risk groups==
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] has become fixed to adjoining structures like the [[rectum]] or [[pelvic wall]]
While TNM staging is important, the TNM stage alone is not sufficient for deciding what treatment is best for a patient with prostate cancer.  Instead, a different category called "risk groups" is used, which is based on the T-stage of the TNM system and adds additional information from the [[Gleason score]] and [[prostate specific antigen]] (PSA) value.  The risk can be described as ''low risk'', ''intermediate risk'', or ''high risk''.  The risk is a useful predictor of having extraprostatic extension, which is spread of the cancer beyond the prostate gland itself.  Although slightly different criteria are used for assigning risk, one such system defines ''low risk'' as a PSA less than 10, a Gleason score of 6 or lower, and a T-stage of T2a or lower; ''high risk'' is a PSA more than 20, a Gleason score of 8 or higher, or T2c; ''intermediate risk'' is a PSA of 10 to 20, T2b, or a Gleason of 7.
|-
| style="padding: 5px 5px; background: #DCDCDC;" |any T
| style="padding: 5px 5px; background: #DCDCDC;" |N1
| style="padding: 5px 5px; background: #DCDCDC;" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has spread to regional [[lymph nodes]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" |any T
| style="padding: 5px 5px; background: #DCDCDC;" |any N
| style="padding: 5px 5px; background: #DCDCDC;" |M1
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor has spread to distant sites such as [[lungs]] or [[liver]]
|}


Patients with low risk disease may be treated with [[prostatectomy]] or [[radiotherapy]] alone.  Patients with intermediate risk disease are usually treated with radiotherapy and a short duration (less than 6 months) of hormonal ablation (medical castration using a [[gonadotropin-releasing hormone analog]]), and those with high risk disease are usually treated with radiotherapy and a long duration of hormonal ablation.
==References==
{{Reflist|2}}


[[Category:Andrology]]
[[Category:Disease]]
[[Category:Urology]]
[[Category:Urology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
{{SIB}}


{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Urology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]

Latest revision as of 05:17, 6 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Steven C. Campbell, M.D., Ph.D. Syed Musadiq Ali M.B.B.S.[2]

Prostate cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Prostate Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Alternative Therapy

Case Studies

Case #1

Prostate cancer staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Prostate cancer staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Prostate cancer staging

CDC on Prostate cancer staging

Prostate cancer staging in the news

Blogs on Prostate cancer staging

Directions to Hospitals Treating Prostate cancer

Risk calculators and risk factors for Prostate cancer staging

Overview

Prostate cancer may be classified into several subtypes based on TNM system and UICC.

TNM staging

Evaluation of the (primary) tumor ('T')[1]

T Definition
TX Cannot evaluate the primary tumor
T0 No evidence of tumor
T1 Tumor present, but not detectable clinically or with imaging
T1a Tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons)
T1b Tumor was incidentally found in greater than 5% of prostate tissue resected
T1c Tumor was found in a needle biopsy performed due to an elevated serum PSA
T2 Tumor can be felt (palpated) on examination, but has not spread outside the prostate
T2a Tumor is in half or less than half of one of the prostate gland's two lobes
T2b Tumor is in more than half of one lobe, but not both
T2c Tumor is in both lobes
T3 Tumor has spread through the prostatic capsule (if it is only part-way through, it is still T2)
T3a Tumor has spread through the capsule on one or both sides
T3b Tumor has invaded one or both seminal vesicles
T4 Tumor has invaded other nearby structures

Evaluation of the regional lymph nodes ('N')

N Definition
NX Cannot evaluate the regional lymph nodes
N0 There has been no spread to the regional lymph nodes
N1 There has been spread to the regional lymph nodes

Evaluation of distant metastasis ('M')

M Definition
M0 There is no distant metastasis
M1 There is distant metastasis

UICC staging

The UICC further groups the TNM data into the stages listed in the table below:[2]

  • Stage I
T N M Definition
T1, T2a N0 M0 Tumor involves half a lobe or less
  • Stage II
T N M Definition
T2b, T2c N0 M0 Tumor involves more than half a lobe but is limited to the prostate
  • Stage III
T N M Definition
T3 N0 M0 Tumor has spread beyond the prostatic capsule or into the bladder neck or seminal vesicles
  • Stage IV
T N M Definition
T4 N0 M0 Tumor has become fixed to adjoining structures like the rectum or pelvic wall
any T N1 M0 Tumor has spread to regional lymph nodes
any T any N M1 Tumor has spread to distant sites such as lungs or liver

References

  1. ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq
  2. ↑ "Stages of prostate cancer".

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Prostate_cancer_staging&oldid=1546116"